Gene expression profiling further unravelled a gene signature correlated with ZBTB38 expression in localised tumours that suggests increased efficacy of a ROS-generating drug, doxorubicin, in tumours with low expression levels of ZBTB38. Consistently, we demonstrated that depletion of ZBTB38 in prostate cancer cell lines caused heightened levels of ROS and higher sensitivity to doxorubicin treatment. Here, ZBTB38 is linked to prostate carcinoma.